SCHEMBL16620495

SCHEMBL16620495

O=C(CCCCC(=O)ON1C(=O)CCC1=O)OCc1ccccc1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.47
L3MBTL1 Q9Y468 2/20 0.47
MAPK1 P28482 1/20 0.47
NOTUM Q6P988 1/20 0.47
EPHX2 P34913 1/20 0.45
FAAH O00519 1/20 0.42
MGLL Q99685 1/20 0.42
LMNA P02545 2/20 0.41
CDC25B P30305 1/20 0.41
TDP1 Q9NUW8 2/20 0.41
KMT2A Q03164 2/20 0.41
SLC6A2 P23975 1/20 0.41
SLC6A3 Q01959 1/20 0.41
SMN1; SMN2 Q16637 2/20 0.40
GLA P06280 1/20 0.40
TPSAB1 Q15661 2/20 0.40
TPSD1 Q9BZJ3 2/20 0.40
TPSG1 Q9NRR2 2/20 0.40
PLG P00747 1/20 0.40
ELANE P08246 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28612301 0.99 EPHX2 (0.46) ALDH1A1L3MBTL1MAPK1NOTUMEPHX2
SCHEMBL4271195 0.99 EPHX2 (0.46) ALDH1A1L3MBTL1MAPK1NOTUMEPHX2
SCHEMBL2151608 0.99 EPHX2 (0.46) ALDH1A1L3MBTL1MAPK1NOTUMEPHX2
SCHEMBL16620483 0.99 EPHX2 (0.46) ALDH1A1L3MBTL1MAPK1NOTUMEPHX2
SCHEMBL8379196 0.99 EPHX2 (0.46) ALDH1A1L3MBTL1MAPK1NOTUMEPHX2
SCHEMBL24996850 0.99 EPHX2 (0.46) ALDH1A1L3MBTL1MAPK1NOTUMEPHX2
SCHEMBL8719966 0.97 ALDH1A1 (0.47) ALDH1A1L3MBTL1MAPK1NOTUMEPHX2
SCHEMBL15450611 0.94 NOTUM (0.52) ALDH1A1L3MBTL1MAPK1NOTUMLMNA
Tetrahydrofuran SCHEMBL8376675 0.92 MEN1 (0.44) ALDH1A1L3MBTL1MAPK1NOTUMEPHX2
SCHEMBL19049879 0.89 ALDH1A1 (0.39) ALDH1A1L3MBTL1MAPK1NOTUMEPHX2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 60 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260021190-A1 GLUCOSE-RESPONSIVE INSULIN CONJUGATES COMPRISING A PENTA-VALENT SUGAR CLUSTER FOR TREATMENT OF DIABETES MERCK SHARP & DOHME LLC (US) 2026-01-22 US disclosed
US-12427187-B2 Glucose-responsive insulin conjugates MERCK SHARP & DOHME LLC (US) 2025-09-30 US disclosed
EP-4615487-A1 GLUCOSE-RESPONSIVE INSULIN CONJUGATES COMPRISING A PENTA-VALENT SUGAR CLUSTER FOR TREATMENT OF DIABETES Merck Sharp & Dohme LLC (US) 2025-09-17 EP disclosed
EP-3660040-B1 INSULIN RECEPTOR PARTIAL AGONISTS MERCK SHARP & DOHME LLC (US) 2025-06-18 EP disclosed
US-20240424109-A1 GLUCOSE-RESPONSIVE INSULIN CONJUGATES COMPRISING A TETRA-VALENT SUGAR CLUSTER FOR TREATMENT OF DIABETES MERCK SHARP & DOHME LLC (US) 2024-12-26 US disclosed
EP-3666792-B1 INSULIN RECEPTOR PARTIAL AGONISTS MERCK SHARP & DOHME LLC (US) 2024-12-18 EP disclosed
EP-4436610-A1 GLUCOSE-RESPONSIVE INSULIN CONJUGATES COMPRISING A TETRA-VALENT SUGAR CLUSTER FOR TREATMENT OF DIABETES Merck Sharp & Dohme LLC (US) 2024-10-02 EP disclosed
WO-2024102633-A1 GLUCOSE-RESPONSIVE INSULIN CONJUGATES COMPRISING A PENTA-VALENT SUGAR CLUSTER FOR TREATMENT OF DIABETES MERCK SHARP & DOHME LLC (US) 2024-05-16 WO disclosed
CN-112494656-B Insulin receptor partial agonists 默沙东有限责任公司 2024-01-30 CN disclosed
US-11820805-B2 Conjugate based systems for controlled insulin delivery MERCK SHARP & DOHME LLC (US) 2023-11-21 US disclosed
EP-3221343-A2 INSULIN RECEPTOR PARTIAL AGONISTS Merck Sharp & Dohme Corp. (US) 2017-09-27 EP disclosed
US-20170107268-A1 INSULIN RECEPTOR PARTIAL AGONISTS MERCK SHARP & DOHME CORP. (US) 2017-04-20 US disclosed
US-20160303244-A1 GLUCOSE-RESPONSIVE INSULIN CONJUGATES MERCK SHARP & DOHME CORP. (US) 2016-10-20 US disclosed
WO-2016164288-A1 GLUCOSE-RESPONSIVE INSULIN CONJUGATES MERCK SHARP & DOHME CORP. (US) 2016-10-13 WO disclosed
US-20160251407-A1 GLUCOSE-RESPONSIVE INSULIN CONJUGATES MERCK SHARP & DOHME CORP. (US) 2016-09-01 US disclosed
US-9427475-B2 Glucose-responsive insulin conjugates MERCK SHARP & DOHME CORP. (US) 2016-08-30 US disclosed
EP-3052134-A2 GLUCOSE-RESPONSIVE INSULIN CONJUGATES Merck Sharp & Dohme Corp. (US) 2016-08-10 EP disclosed
WO-2016081670-A2 INSULIN RECEPTOR PARTIAL AGONISTS MERCK SHARP & DOHME CORP. (US) 2016-05-26 WO disclosed
US-20150105317-A1 GLUCOSE-RESPONSIVE INSULIN CONJUGATES MERCK SHARP & DOHME LLC 2015-04-16 US disclosed
WO-2015051052-A2 GLUCOSE-RESPONSIVE INSULIN CONJUGATES MERCK SHARP & DOHME CORP. (US) 2015-04-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12427187-B2 Glucose-responsive insulin conjugates GPR119, IRS1, INSR ALDH1A1 4239/4885L3MBTL1 1420/4885MAPK1 931/4885
US-20150105317-A1 GLUCOSE-RESPONSIVE INSULIN CONJUGATES GPR119, INSR, IRS1 ALDH1A1 3285/4885L3MBTL1 1526/4885MAPK1 1090/4885
US-11820805-B2 Conjugate based systems for controlled insulin delivery GPR119, INSR, IGF1R ALDH1A1 1357/4885L3MBTL1 1567/4885MAPK1 4342/4885
US-20260021190-A1 GLUCOSE-RESPONSIVE INSULIN CONJUGATES COMPRISING A PENTA-VALENT SUGAR CLUSTER FOR TREATMENT OF DIABETES INSR, GPR119, GLP1R ALDH1A1 2398/4885L3MBTL1 2640/4885MAPK1 3293/4885
US-20160251407-A1 GLUCOSE-RESPONSIVE INSULIN CONJUGATES GPR119, INSR, IRS1 ALDH1A1 3459/4885L3MBTL1 1356/4885MAPK1 1013/4885
US-20240424109-A1 GLUCOSE-RESPONSIVE INSULIN CONJUGATES COMPRISING A TETRA-VALENT SUGAR CLUSTER FOR TREATMENT OF DIABETES GPR119, INSR, IAPP ALDH1A1 4123/4885L3MBTL1 1842/4885MAPK1 2453/4885
US-20170107268-A1 INSULIN RECEPTOR PARTIAL AGONISTS INSR, GPR119, IRS1 ALDH1A1 4716/4885L3MBTL1 3741/4885MAPK1 3170/4885
US-20160303244-A1 GLUCOSE-RESPONSIVE INSULIN CONJUGATES GPR119, INSR, IRS1 ALDH1A1 3285/4885L3MBTL1 1526/4885MAPK1 1090/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.